#Fumaderm

[phonemantra-blog]

Understanding Dimethyl Fumarate: A Versatile Compound Dimethyl Fumarate (DMF) is a chemical compound with a wide range of applications in various industries, from pharmaceuticals to textiles. In this article, we'll delve into the world of DMF, exploring its uses, benefits, and importance in today's world. What Is Dimethyl Fumarate (DMF)? Dimethyl Fumarate, often abbreviated as DMF, is an organic compound with the molecular formula C6H8O4. It is a white, crystalline substance with a slightly sweet odor. DMF is known for its remarkable versatility and is used in different fields due to its unique properties. [caption id="attachment_55657" align="aligncenter" width="2560"] dimethyl fumarate[/caption] The Diverse Applications of Dimethyl Fumarate DMF has found its way into a multitude of industries, each benefiting from its specific properties and functions. Let's explore some of the key applications of DMF: In Pharmaceutical Industry In the pharmaceutical sector, DMF plays a crucial role as an active pharmaceutical ingredient (API) in the formulation of medications. One of its notable applications is in the treatment of multiple sclerosis. In Textile and Fabrics Another prominent use of DMF is in the textile industry, where it acts as a highly effective antimicrobial and anti-fungal agent. Fabrics treated with DMF are more resistant to mold, mildew, and bacterial growth, making them ideal for various applications, including sportswear and outdoor gear. In Electronics and Plastics DMF is a valuable solvent and processing aid in the production of various electronic components and plastics. It aids in the manufacture of polymers, ensuring uniformity and quality in the final products. Safety and Regulatory Aspects of Dimethyl Fumarate While Dimethyl Fumarate (DMF) offers a wide range of benefits across various industries, it's essential to understand the safety measures and regulatory considerations associated with its usage. Safety Precautions When handling DMF, it's crucial to adhere to safety precautions to minimize potential risks: Protective Gear: Wear appropriate protective gear, including gloves and safety goggles, when working with DMF to prevent skin contact and eye irritation. Ventilation: Ensure adequate ventilation in areas where DMF is used to minimize inhalation exposure. Storage: Store DMF in well-sealed containers away from incompatible substances and in a cool, dry place. Regulatory Compliance DMF is subject to various regulatory standards and guidelines, depending on its intended use. It's important to stay compliant with these regulations to ensure safety and quality. Regulatory bodies such as the Food and Drug Administration (FDA) oversee the use of DMF in pharmaceuticals, while environmental agencies monitor its impact on the environment. Future Trends and Research The applications of DMF continue to evolve, driven by ongoing research and technological advancements. Here are some emerging trends and areas of research related to DMF: Sustainable Production Efforts are underway to develop more sustainable methods for the production of DMF, with a focus on reducing environmental impact and resource consumption. Medical Innovations Researchers are exploring new medical applications of DMF beyond multiple sclerosis treatment, including its potential in autoimmune disorders and cancer therapies. Improved Textile Treatments In the textile industry, scientists are working on innovative methods to enhance the durability and effectiveness of DMF-treated fabrics, opening up new possibilities in fashion and sportswear. Frequently Asked Questions (FAQs) About Dimethyl Fumarate (DMF) What is Dimethyl Fumarate (DMF)? DMF is an organic compound with the molecular formula C6H8O4. It is a versatile chemical with applications in various industries. What are the primary uses of DMF? DMF is used in pharmaceuticals, textiles, electronics, and plastics. It's an active pharmaceutical ingredient, an antimicrobial agent in textiles, and a solvent in electronics and plastics manufacturing. How is DMF used in the pharmaceutical industry? DMF is used in the treatment of relapsing forms of multiple sclerosis. It has shown effectiveness in reducing relapse frequency and slowing disease progression. Is DMF safe to handle? DMF should be handled with care. Safety precautions include wearing protective gear, ensuring proper ventilation, and avoiding skin contact and inhalation of vapors. Are there regulatory guidelines for DMF usage? Yes, regulatory bodies like the FDA oversee DMF's usage in pharmaceuticals, and environmental agencies monitor its impact on the environment. What are the emerging trends in DMF research? Research is focusing on sustainable production methods, exploring new medical applications beyond multiple sclerosis, and improving textile treatments using DMF. Can DMF be used in cancer treatment? Ongoing research is exploring DMF's potential in cancer therapies and autoimmune disorders, but more studies are needed to establish its efficacy. Is DMF environmentally friendly? Efforts are underway to make DMF production more sustainable and environmentally friendly. What are the key properties of DMF? DMF is a white crystalline powder with a slightly sweet odor and is sparingly soluble in water. Where can I stay updated on the latest DMF developments? You can stay informed about DMF advancements through scientific journals, industry news, and regulatory agencies' publications. Conclusion: Dimethyl Fumarate (DMF) has cemented its place as a versatile compound with diverse applications across multiple industries. From improving the quality of life for multiple sclerosis patients to enhancing the durability of textiles, DMF continues to impact our lives in meaningful ways.

[azveille]

La CT défavorable au remboursement de l'antipsoriasique Skilarence* et de Lenvima* dans le cancer du foie

La commission de la transparence (CT) a estimé que Skilarence* (diméthyl fumarate, Almirall) dans le psoriasis et Lenvima* (lenvatinib, Eisai/Merck & Co) dans le carcinome hépatocellulaire apportaient un service médical rendu (SMR) insuffisant pour justifier leur remboursement, selon des avis mis en ligne la semaine dernière par la Haute autorité de santé (HAS).

Skilarence* a décroché une autorisation de mise sur le marché (AMM) européenne centralisée en juin 2017 dans le traitement des patients adultes atteints de psoriasis en plaques modéré à sévère nécessitant un traitement systémique.

Saisie d'une demande d'inscription au remboursement en ville et d'agrément aux collectivités, la CT a considéré que le SMR du médicament était insuffisant "au regard des thérapies disponibles" et qu'il n'avait pas sa place dans la stratégie thérapeutique.

Elle évoque la faible efficacité de Skilarence*, "démontrée uniquement versus placebo dans un contexte où une comparaison versus traitement actif était réalisable, sur un critère de jugement (PASI 75) peu contraignant en matière de réponse clinique à atteindre au regard de l’efficacité des traitements les plus récents".

Elle pointe dans la population per protocole une absence de démonstration de la non-infériorité de Skilarence* versus Fumaderm* (Fumapharm), médicament à base d’esters d’acide fumarique sans AMM en France (mais homologué en Allemagne). Elle regrette aussi l’absence de comparaison aux traitements systémiques biologiques et non biologiques disponibles en France, ainsi que l’absence de données de qualité de vie, d’efficacité et de tolérance à long terme.

Le médicament est par ailleurs associé à de "nombreux" risques (en particulier des troubles gastro-intestinaux, des bouffées congestives et des troubles hématologiques), dont certains "potentiellement graves" (troubles hépatiques, rénaux, hématologiques, cancer et risques d’infections graves dont une leuco-encéphalopathie multifocale progressive -Lemp).

S'agissant de Lenvima*, Eisai sollicitait un remboursement en ville et un agrément aux collectivités dans une extension d'indication européenne obtenue en août 2018 en monothérapie dans le traitement du carcinome hépatocellulaire avancé ou non résécable chez les adultes qui n’ont pas reçu de traitement systémique antérieur.

Là encore, la CT a jugé que le SMR du médicament était insuffisant dans cette indication "au regard des thérapies disponibles". Eisai revendiquait un SMR important et une absence d'amélioration du SMR (ASMR V) uniquement chez les patients dont la fonction hépatique est préservée (stade Child-Pugh A).

Elle dit avoir basé son analyse sur "la démonstration de la non-infériorité (sans démonstration de la supériorité) du lenvatinib par rapport au sorafénib en termes de survie globale" et souligne "les limites méthodologiques de cette démonstration" (population très sélectionnée, étude réalisée en ouvert, possibilité pour les patients du groupe lenvatinib d’être traités par sorafénib en cas de progression de la maladie alors que l’inverse n’était pas possible, notamment).

Elle s'inquiète de la transposabilité des résultats de l'étude pivot en France, les patients inclus étant en majorité originaires d’Asie-Pacifique, où la répartition des étiologies de l’hépatocarcinome ne correspond pas à l’épidémiologie française.

La CT met également en avant le profil de tolérance "dégradé" du lenvatinib vs le sorafénib, avec une fréquence supérieure d’événements indésirables graves, d’événements de grade supérieur ou égal à 3 et de décès dans le groupe lenvatinib par rapport au groupe sorafénib.

Enfin, elle évoque "l’impossibilité d’identifier les patients qui ne pourraient pas recevoir le sorafénib mais seraient éligibles au lenvatinib", les deux médicaments appartenant à la même classe pharmaco-thérapeutique. Elle estime donc qu’"une perte de chance pour le patient de recevoir Lenvima* ne peut être exclue et que l’utilisation du sorafénib doit donc être privilégiée".

Lenvima* est pris en charge en France depuis début 2017 dans le cancer de la thyroïde, rappelle-t-on (cf dépêche du 10/01/2017 à 11:08).

[hillcountrytimes]

Morrison Wm Supermarkets PLC (LON:MRW) Investors: Deutsche Bank Maintains “Hold” Rating; Biogen Idec (BIIB) Has 0.92 Sentiment

In analysts report sent to clients and investors by Deutsche Bank on 6 March, Morrison Wm Supermarkets PLC (LON:MRW) stock “Hold” was kept.

Biogen Inc. is a biopharmaceutical company. The company has market cap of $65.23 billion. The Firm focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. It has a 17.61 P/E ratio. The Firm markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis , FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Sarissa Capital Management Lp holds 24.21% of its portfolio in Biogen Inc for 310,000 shares. Tekla Capital Management Llc owns 537,350 shares or 6.49% of their US portfolio. Moreover, Iguana Healthcare Management Llc has 5.93% invested in the company for 35,000 shares. The Missouri-based Terril Brothers Inc. has invested 5.85% in the stock. Partner Investment Management L.P., a California-based fund reported 12,933 shares.

Since January 1, 0001, it had 1 insider purchase, and 6 sales for $10.38 million activity.

Ratings analysis reveals 70% of Biogen Idec Inc.’s analysts are positive. Out of 20 Wall Street analysts rating Biogen Idec Inc., 14 give it “Buy”, 0 “Sell” rating, while 6 recommend “Hold”. The lowest target is $268 while the high is $450. The stock’s average target of $349.71 is 17.45% above today’s ($297.75) share price. BIIB was included in 38 notes of analysts from July 23, 2015. The company was maintained on Friday, March 11 by Robert W. Baird. The stock has “Neutral” rating by Robert W. Baird on Monday, July 27. The rating was maintained by Cowen & Co on Tuesday, August 25 with “Buy”. The firm earned “Buy” rating on Thursday, January 7 by Standpoint Research. Wells Fargo maintained the stock with “Outperform” rating in Friday, December 4 report. The firm has “Neutral” rating by Credit Suisse given on Wednesday, January 20. The firm earned “Outperform” rating on Wednesday, October 7 by RBC Capital Markets. The stock of Biogen Inc (NASDAQ:BIIB) earned “Overweight” rating by Piper Jaffray on Thursday, November 5. As per Monday, November 7, the company rating was upgraded by Leerink Swann. Atlantic Securities initiated the shares of BIIB in report on Friday, December 18 with “Overweight” rating.

The stock increased 1.42% or $4.16 on March 3, reaching $297.75. About shares traded. Biogen Inc (NASDAQ:BIIB) has risen 3.05% since July 28, 2016 and is uptrending. It has underperformed by 6.77% the S&P500.

Wm Morrison Supermarkets PLC is engaged in the operation of retail supermarket stores under the Morrisons brand and associated activities. The company has market cap of 5.73 billion GBP. The Firm offers products, such as Free From, World Foods, Food To Go and Nutmeg clothing. It has a 25.61 P/E ratio. It has food manufacturing capabilities in meat, fish, bakery, fruit and veg, deli and flowers.

The post Morrison Wm Supermarkets PLC (LON:MRW) Investors: Deutsche Bank Maintains “Hold” Rating; Biogen Idec (BIIB) Has 0.92 Sentiment appeared first on Stock Market News | HillCountryTimes | Get it Today.

from Stock Market News | HillCountryTimes | Get it Today https://www.hillcountrytimes.com/2017/03/06/morrison-wm-supermarkets-plc-lonmrw-investors-deutsche-bank-maintains-hold-rating-biogen-idec-biib-has-0-92-sentiment/